Sun, Apr 20, 2014, 3:08 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • usagary1 usagary1 Mar 15, 2013 8:14 AM Flag

    wow..see new p53 patent

    METHODS AND COMPOSITIONS FOR MANIPULATING TRANSLATION OF PROTEIN ISOFORMS FROM ALTERNATIVE INITIATION START SITES
    Document Type and Number:
    WIPO Patent Application WO/2013/012752

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Can't find it on the US Patent App. site. Who is the "assignnee" or "inventor"? Thanks.

      • 1 Reply to copphiggins
      • Inventors:
        IVERSEN, Patrick, L. (5902 Northwest Fair Oaks Place, Corvallis, Oregon, 97330, US)
        Application Number:
        US2012/046783
        Publication Date:
        January 24, 2013

        Assignee:
        SAREPTA THERAPEUTICS, INC. (3450 Monte Villa Parkway, Suite 101Bothell, Washington, 98021, US)
        IVERSEN, Patrick, L. (5902 Northwest Fair Oaks Place, Corvallis, Oregon, 97330, US)
        International Classes:
        C12N15/113

        Attorney, Agent or Firm:
        HUNDLEY, Jeffrey, E. et al. (Seed Intellectual Property Law Group PLLC, Suite 5400701 Fifth Avenue, Seattle Washington, 98104-7064, US)

    • just a small part of this patent//freaking wow.
      -------------------------------------------------------------
      In some embodiments, provided herein is a pharmaceutical composition comprising an isolated antisense oligonucleotide as described herein and a

      pharmaceutically acceptable carrier. In some embodiments, provided herein is a method of increasing translation of said second isoform comprising hybridizing an isolated antisense oligonucleotide as described herein to said start codon. In one aspect, provided herein is an antisense oligonucleotide of 12 to 50 nucleotides in length comprising a sequence substantially complementary to a translation start codon of an mRNA that encodes at least two cellular protein isoforms translated from at least two translation start codons of said mRNA for the treatment of a disease. Antisense oligonucleotides for use in the treatment of disease can be any antisense oligonucleotide provided herein. In some embodiments, the disease is a proliferative disorder,

      Alzheimer's disease, diabetes, a neurodegenerative disorder, a TAR DNA-binding protein-43 (TBP-43) proteinopathy, amytrophic lateral sclerosis, or leukemia. In some embodiments of the methods and compositions provided herein, the m NA encodes a member of a cell signaling pathway. In some embodiments, the mR A encodes a mammalian protein, such as a human protein. In some embodiments, the mRNA encodes a viral protein, such as a foot-and-mouth disease protein. In some embodiments, the mRNA encodes a protein selected from the group consisting of p53, FGF2, VEGF-A, c-Myc, n-Myc, 1-Myc, LYL1, pl5 INK4B, WT1, BAG1, NOD2, Caspase 8, Catechol O methyl transferase, EGF3, EIF4G1, GATA1, TRIIA-alpha, IL- lra, MAP3K8, NFATC1, SHC, SOCS3, RAG1, IDE, TDP-43, and RGS2.

      In some embodiments of the methods and compositions provided herein, the antisense oligonucleotide inhibits cell cycle progression. In some embodiments, the antisense oligonucleotide enhances sensitivity of tumor cells to ch

    • clearly proves that Sarepta will be in the Cancer market as well..........

 
SRPT
24.40+0.17(+0.70%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.